A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs TD 8954 (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Pharmacokinetics
- Sponsors Takeda
- 18 Dec 2018 Planned End Date changed from 21 Dec 2018 to 9 May 2019.
- 18 Dec 2018 Planned primary completion date changed from 21 Dec 2018 to 9 May 2019.
- 05 Jan 2018 Status changed from not yet recruiting to recruiting.